Aliquots of the RNA preparations were then RT‐PCR amplified with primer pairs specific for five human genes using a Light‐Cycler. The cells were cultured overnight at 37☌ under non‐adherent conditions, collected, lysed, and total RNA prepared. Methods: Blood samples were obtained from patients with ALS and controls after obtaining informed consent and mononuclear cells were isolated by Percoll gradient centrifugation. Objective: To evaluate the utility of a quantitative RT‐PCR assay of peripheral blood cells for the classification of samples as derived from ALS patients or controls. This raises the possibility that diagnosis of ALS can be assisted by molecular analysis of blood specimens. Yu S 1, Do H 1, Mass J 2, Katz J 2, Zhang R 3, Gascon R 3, Lancero M 1, Miller RG 2, McGrath MS 3 & Hadlock KG 1ġPathologica LLC, Burlingame, 2Forbes Norris MDA/ALS Research Center, San Francisco, and 3University of California, San Francisco, San Francisco, USAĮ‐mail address for correspondence: Recent work by our group has established that blood macrophages from individuals with amyotrophic lateral sclerosis (ALS) have significant changes in their transcriptional program compared to healthy individuals. P92 DETECTION OF ALS BY QUANTITATIVE REAL TIME RT‐PCR OF PERIPHERAL BLOOD CELLS P113 MUSCLE AND JOINT PAIN IN MND/POST‐POLIOMYELITIS (PPS).
DIAGNOSTIC VENTILATION CENON SERIES
P112 CLINICAL AND NEUROPATHOLOGICAL STUDY OF A SERIES OF ALS‐DEMENTIA SYNDROME PATIENTS: ANALYSIS OF OUR EXPERIENCE.P111 FLAIL‐LIMB VARIANT OF MOTOR NEURON DISEASE HAS EVIDENCE OF CENTRAL AND PERIPHERAL NERVE DYSFUNCTION.P110 ASSESSMENT OF RESPIRATORY FUNCTION, SLEEP QUALITY AND ACTIVITIES OF DAILY LIVING IN PLS PATIENTS.P109 PRIMARY LATERAL SCLEROSIS AND AMYOTROPHIC LATERAL SCLEROSIS DISPLAY DIFFERENCES AT DISEASE ONSET AND DURING FOLLOW‐UP THAT CAN HELP DIFFERENTIATE THE TWO ILLNESSES.P108 THE CLINICAL SPECTRUM OF SPORADIC ADULT‐ONSET UPPER MOTOR NEURON DISEASE.P107 MILD EVOLUTION IN A SUBSET OF ALS/MND CASES WITH BULBAR ONSET: A DIFFERENTIAL DIAGNOSIS?.P106 SEVERE PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS AFTER INTERVERTEBRAL DISCECTOMY.P105 THE RATE OF WEIGHT LOSS AND NOT BODY MASS INDEX IS A STRONG PROGNOSTIC FACTOR IN ALS.P104 HEPATITIS: AN ADVERSE EVENT DURING THE TREATMENT OF ALS WITH RILUZOLE OF HETEROGENEOUS ORIGIN.P103 STUDY OF RILUZOLE IN A PROSPECTIVE COHORT OF 501 SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS).P102 BULBAR FEATURE ASSESSMENT: A MULTILEVEL APPROACH.P101 FINDING AN INDIVIDUALIZED METHOD FOR MEASURING PROGRESSION IN ALS CLINICAL TRIALS.P100 MULTI‐DRUG ‘COCKTAIL’ THERAPY IN ALS: A FEASIBILITY AND SAFETY STUDY.P99 A HISTORICAL DATABASE CONTROLLED PHASE II STUDY OF INTERFERON BETA 1A TREATMENT IN ALS.
DIAGNOSTIC VENTILATION CENON TRIAL
P98 PHASE 2B RANDOMIZED DOSE‐RANGING CLINICAL TRIAL OF TAMOXIFEN, A SELECTIVE ESTROGEN RECEPTOR MODULATOR, IN AMYOTROPHIC LATERAL SCLEROSIS (ALS): SENSITIVITY ANALYSES OF DISCORDANCE BETWEEN SURVIVAL AND FUNCTIONAL OUTCOMES WITH LONG‐TERM FOLLOW‐UP.P97 THE SKELETAL MUSCLE TRANSCRIPTOME IN AMYOTROPHIC LATERAL SCLEROSIS.
0 kommentar(er)
